Budesonide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), NYE METODER (Norway) and PHARMAC (New Zealand), among others, recommended or restricted budesonide, while AIFA (Italy) did not recommend it.
PHARMAC (New Zealand) has been easier on budesonide than on its own caseload: it refused 0 of 10 decisive submissions here (0%), against a base rate of 29% across everything it has assessed.
The file has been open for more than a decade: 24.8 years separate the first record, 23 Aug 2001 at PHARMAC (New Zealand), from the most recent, 26 May 2026 at AWMSG (Wales).
CIPM (Spain) changed its position: not recommended on 5 May 2022, recommended by 26 Mar 2025, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for budesonide, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 13 of 76 records date from 2023 or later.
The programme is broad: 19 distinct indication wordings are recorded for budesonide by the agencies that label one in English (AWMSG, PBAC and SMC).
16 of these 76 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess budesonide, on 23 Aug 2001; AIFA (Italy) did not open a file until 24 Mar 2025 — an unusually long tail of 23.6 years between the earliest and latest system to look at it.
The record arrives in waves: 16 separate years each carry two or more decisions, spread across 19 years in total.
8 of the 12 agencies here assessed budesonide more than once, HAS (France) most often at 23 entries — repeat review is the norm for this molecule rather than the exception.
budesonide has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for budesonide reads 40 recommended, 11 not recommended, 7 not assessed and 7 other, with 11 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 16 Mar 2026 | programu lekowego B.171. „Leczenie pacjentów z pierwotną nefropatią IgA (ICD-10: N02.8) | not recommended | source |
| HAS (France) | 14 Jan 2026 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| CIPM (Spain) | 26 Mar 2025 | Indicaciones terapéuticas autorizadas: Kinpeygo está indicado para el tratamiento de adultos con nefropatía por inmunogl… | financed by the SNS · art. 92 a, c | source |
| AIFA (Italy) | 24 Mar 2025 | Kinpeygo è indicato per il trattamento della nefropatia primaria da immunoglobulina A (nefropatia primaria da IgA, IgAN)… | not reimbursed (class C) | source |
| DMC (Denmark) | 25 Sep 2024 | Behandling af primær immunglobulin A (IgA)-nefropati (IgAN) hos voksne med risiko for hurtig sygdomsprogression med et u… | Ikke anbefalet | source |
71 further decisions for budesonide, across 11 agencies, are not shown here. They include the most recent record on file, 26 May 2026 from AWMSG (Wales); its outcome is in the subscriber dataset. They link to 47 further source documents.
Related molecules
- sparsentan — divergent outcome (recommended vs other) on a shared indication
- mesalazine — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone / formoterol — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone / formoterol / glycopyrronium — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- prednisolone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
Coverage: 76 decisions for budesonide from 12 agencies, 2001 to 2026. Data to 7 Sep 2026. ATC class A07E — Antidiarrheals / intestinal anti-inflammatories. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.